Sana Biotechnology Q1 net loss $82.1M; advancing SC291 trial with data expected H2 2023

Sana Biotechnology, Inc.

2023-Q1 EPS reported -$0.43

Cash $355.1M, supports operations into 2025; non-GAAP operating cash burn $74.8M for Q1.
SC291 Phase 1 ARDENT trial enrolling; granted Fast Track for r/r large B-cell lymphoma and CLL.
Plan to file INDs for SC262 and SG299 in H2 2023; SC451 IND in 2024.
Appointed Dr. Doug Williams as President of R&D and Dr. Gary Meininger as CMO.
Net loss $82.1M ($0.43/share) vs $31.4M ($0.17) prior year; R&D expense $67.2M down 7.6%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sana Biotechnology, Inc. reported financial results for the quarter and year ended March 31, 2023.

Period: the quarter and year ended March 31, 2023
Result: reported results

Exact text from the filing

On May 8, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended March 31, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-007072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.